This company listing is no longer active
Salud financiera de hoja de balance de FUREN Group PharmaceuticalLtd
Salud financiera controles de criterios 2/6
FUREN Group PharmaceuticalLtd has a total shareholder equity of CN¥-2.2B and total debt of CN¥3.2B, which brings its debt-to-equity ratio to -144.8%. Its total assets and total liabilities are CN¥6.2B and CN¥8.4B respectively.
Información clave
-144.8%
Ratio deuda-patrimonio
CN¥3.21b
Deuda
Ratio de cobertura de intereses | n/a |
Efectivo | CN¥173.80m |
Patrimonio | -CN¥2.22b |
Total pasivo | CN¥8.39b |
Activos totales | CN¥6.18b |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
Análisis de la situación financiera
Pasivos a corto plazo: 600781 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Pasivo a largo plazo: 600781 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Historial y análisis de deuda-patrimonio
Nivel de deuda: 600781 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducción de la deuda: 600781's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: Whilst unprofitable 600781 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Pronóstico de cash runway: 600781 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 6.6% per year.